Ocugen Inc. (OCGN): Price and Financial Metrics
OCGN Price/Volume Stats
| Current price | $0.76 | 52-week high | $2.03 |
| Prev. close | $0.71 | 52-week low | $0.52 |
| Day low | $0.68 | Volume | 8,339,400 |
| Day high | $0.81 | Avg. volume | 3,953,182 |
| 50-day MA | $0.67 | Dividend yield | N/A |
| 200-day MA | $0.88 | Market Cap | 221.48M |
OCGN Stock Price Chart Interactive Chart >
Ocugen Inc. (OCGN) Company Bio
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.
OCGN Price Returns
| 1-mo | 11.86% |
| 3-mo | 5.86% |
| 6-mo | -16.59% |
| 1-year | -60.21% |
| 3-year | -63.11% |
| 5-year | 149.18% |
| YTD | -5.59% |
| 2024 | 40.00% |
| 2023 | -55.77% |
| 2022 | -71.43% |
| 2021 | 148.63% |
| 2020 | 251.92% |
Loading social stream, please wait...